Abstract:This study aimed to compare the efficacy and safety of generic exenatide with branded exenatide Byetta® in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on monotherapy or combination therapy of metformin and insulin secretagogues. A multicenter, randomized, controlled, non-inferiority trial was performed. A total of 240 patients with T2DM and glycated hemoglobin (HbA1c) ≥ 7% (53 mmol/mol) to ≤ 9.0% (75 mmol/mol) on monotherapy or combination therapy of metformin and insulin secretagogues for at least 3 months were randomized into generic exenatide or branded exenatide groups with a 1:1 ratio for 16 weeks of treatment. The primary endpoint was the change in HbA1c levels from baseline at week 16, with a non-inferiority margin of − 0.35% (− 3.83 mmol/mol) (lower bound of one-sided 95% confidence interval (CI) > − 0.35% (− 3.83 mmol/mol)). Secondary endpoints included the proportion of participants achieving HbA1c < 7% (53 mmol/mol), the changes in fasting plasma glucose (FPG), 2-h postprandial glucose (2hPG) following a standard meal, 7-point self-monitoring blood glucose (SMBG) profiles, body weight change from baseline at week 16 and the change in HbA1c levels from baseline at week 8. Safety issues were also evaluated. After 16 weeks of treatment, HbA1c levels decreased significantly from baseline in the two groups, with a reduction of − 1.10% ± 1.31% (− 12.0 mmol/mol ± 14.3 mmol/mol) in the generic exenatide group and − 1.08% ± 1.11% (− 11.8 mmol/mol ± 12.1 mmol/mol) in the branded exenatide group (both P < 0.001). The least-squares mean difference of HbA1c reduction between the two groups was − 0.03% (− 0.33 mmol/mol), with a lower one-sided 95% CI limit of − 0.27% (− 2.95 mmol/mol), which was higher than the prespecified non-inferiority margin of − 0.35% (− 3.83 mmol/mol). Moreover, there were no significant differences in the proportion of participants achieving HbA1c < 7% (53 mmol/mol) and the changes in FPG, 2hPG, 7-point SMBG profiles and body weight at week 16 and the change in HbA1c levels from baseline at week 8 (all P > 0.05) between the two groups. The incidence of adverse events, including the incidence of hypoglycemia (18.3% and 17.5%, respectively), was similar for the generic and branded exenatide groups (P > 0.05). In patients with T2DM inadequately controlled on monotherapy or combination therapy of metformin and insulin secretagogues, add-on treatment with generic exenatide demonstrated non-inferiority to branded exenatide in terms of improvements in HbA1c after 16 weeks of treatment. Furthermore, the two drugs were also similar for other efficacy endpoints and safety profile. Trial registration Chinese Clinical Trial Registry: ChiCTR-IPR-15006558, Date registered May 27, 2015.

Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.

Impact of Baseline BMI on Glycemic Control and Weight Change with Exenatide Monotherapy in Chinese Drug-naïve Type 2 Diabetic Patients.

Efficacy and safety of domestic exenatide injection in treating type 2 diabetes: A multicenter, randomized, controlled, and non-inferiority trial

Efficacy and Safety of Exenatide in Patients of Asian Descent with Type 2 Diabetes Inadequately Controlled with Metformin or Metformin and a Sulphonylurea

Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus

Efficacy and Safety of Generic Exenatide Injection in Chinese Patients with Type 2 Diabetes: a Multicenter, Randomized, Controlled, Non-Inferiority Trial.

Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: analysis of results from the CONSENT trial.

Efficacy and safety of exenatide in Chinese patients with type 2 diabetes inadequately controlled with metformin or metformin and a sulfonylurea

Exenatide in the treatment of type 2 diabetes: a health technology assessment

A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes

Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin

Effect of Baseline -Cell Function on Treatment Response to Exenatide in Patients with Newly Diagnosed Type 2 Diabetes

966-P: Effect of Baseline SS-Cell Function on Treatment Response to Exenatide in Patients with Newly Diagnosed Type 2 Diabetes

Cost-Effectiveness Analysis of Exenatide Twice Daily (BID) Versus Insulin Glargine Once Daily (QD) As Add-on Therapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Oral Therapies.

Effects of Exenatide Versus Insulin Glargine on Body Composition in Overweight and Obese T2DM Patients: a Randomized Controlled Trial

Effect of Exenatide after Short-Time Intensive Insulin Therapy on Glycaemic Remission Maintenance in Type 2 Diabetes Patients: a Randomized Controlled Trial

Comparing the Effects of Twice-Daily Exenatide and Insulin on Renal Function in Patients with Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Controlled Trial.

Cost-Effectiveness of Exenatide Twice Daily vs. Insulin Glargine as Add-on Therapy to Oral Antidiabetic Agents in Type 2 Diabetes in China

Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes

Effect of Exenatide on serum fibroblast growth factor-21 level in patients with type 2 diabetes

Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus